French biotech and medical AI platform Surge has raised $2.6 million in funding to decode a patient’s immune system from a blood sample. The pre-seed round was co-led by HCVC and Boutique Venture Partners. Veteran angel investors, including Nicolas Godin, the COO and CFO of Cardiologs, also participated in the round. The funding will enable Surge to conduct clinical studies with other hospitals.
With 30% of major surgeries currently resulting in complications and 40% of patients aged 65 and above suffering long-lasting cognitive impacts after orthopedic or cardiac surgery, Surge’s solution enables targeted and personalised interventions to reduce patients’ risk of postsurgical complications. The startup’s flagship product uses innovative machine learning algorithms to decode a patient’s immune system from a blood sample. This technology enables physicians to quickly forecast the risk of postoperative complications.
Julien Hédou, president and co-founder of Surge said: “We aim to develop the reference solution for surgical precision medicine. We plan to expand and diversify the applications of our technology with immune profiling tools for all surgical complications. Eventually, we also want to apply our methodology to other therapeutic areas.”
Alexis Houssou, founder of HCVC Partners added: “Surge has created strong relationships spanning both the French and American academic worlds, with partners including, AP-HP, and Institut Pasteur, and Stanford building a solid network that will allow them to achieve their goals.”